Pyxis Oncology (PYXS) Common Equity (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Common Equity data on file, last reported at $53.4 million in Q4 2025.

• Common Equity for Q4 2025 came in at $53.4 million, down 55.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $53.4 million (down 55.77% YoY), and the FY2025 annual result was $53.4 million, down 55.77% from the prior year.
• Common Equity fell to $53.4 million in Q4 2025 per PYXS's latest filing, from $68.8 million in the prior quarter.
• Over five years, Common Equity peaked at $261.3 million in Q4 2021 and troughed at -$71.4 million in Q3 2021.
• A 5-year average of $119.0 million and a median of $141.6 million in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 1770.27% in 2021 and fell as far as 544.35% in 2021.
• A 5-year view of Common Equity shows it stood at $261.3 million in 2021, then sank by 38.46% to $160.8 million in 2022, then retreated by 21.84% to $125.7 million in 2023, then slipped by 3.94% to $120.8 million in 2024, then tumbled by 55.77% to $53.4 million in 2025.
• Business Quant data shows PYXS's Common Equity at $53.4 million in Q4 2025, $68.8 million in Q3 2025, and $87.6 million in Q2 2025.